Isabelle Hampele
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Pharmaceutical studies and practices, Drug-Induced Adverse Reactions
Most-Cited Works
- → Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials(2014)1,933 cited
- → Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials(2022)42 cited
- → Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study(2021)17 cited
- → Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial(2021)14 cited
- → Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study(2024)14 cited
- → FAST SYMPTOM IMPROVEMENT AND FAVORABLE SAFETY PROFILE WITH REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA: REMIX-1/-2 STUDIES(2023)7 cited
- → 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE(2021)5 cited
- → L’administration du sécukinumab par un auto-injecteur de 2 mL démontre une efficacité élevée avec une sécurité et une tolérance comparables chez les patients adultes atteints de psoriasis en plaques : résultats à 16 semaines de l’étude MATURE(2021)
- → 27519 Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis(2021)